Exosome (vesicle)

Last updated
Exosome (extracellular vesicle)
Exosome with hsp70.png
Exosome cross-section showing hsp70 protein
Identifiers
MeSH D055354
Anatomical terminology

Exosomes, ranging in size from 30 to 150 nanometers, [1] are membrane-bound extracellular vesicles (EVs) that are produced in the endosomal compartment of most eukaryotic cells. [2] [3] [4] In multicellular organisms, exosomes and other EVs are found in biological fluids including saliva, blood, urine and cerebrospinal fluid. [5] EVs have specialized functions in physiological processes, from coagulation and waste management to intercellular communication. [6]

Contents

Exosomes are formed through the inward budding of a late endosome, also known as a multivesicular body (MVB). [7] The intraluminal vesicles (ILVs) of the multivesicular body (MVB) bud inward into the endosomal lumen. If the MVB fuses with the cell surface (the plasma membrane), these ILVs are released as exosomes. [8] Exosomes were also identified within the tissue matrix, coined Matrix-Bound Nanovesicles (MBV). [9] They are also released in vitro by cultured cells into their growth medium. [6] [10] [11] Enriched with a diverse array of biological elements from their source cells, exosomes contain proteins (such as adhesion molecules, cytoskeletons, cytokines, ribosomal proteins, growth factors, and metabolic enzymes), lipids (including cholesterol, lipid rafts, and ceramides), and nucleic acids (such as DNA, mRNA, and miRNA). [12] Since the size of exosomes is limited by that of the parent MVB, exosomes are generally thought to be smaller than most other EVs, from about 30 to 150 nanometres (nm) in diameter: around the same size as many lipoproteins but much smaller than cells. [13] [6] Compared with EVs in general, it is unclear whether exosomes have unique characteristics or functions or can be separated or distinguished effectively from other EVs. [2]

EVs in circulation carry genetic material and proteins from their cell of origin, proteo-transcriptomic signatures that act as biomarkers. [7] [5] [6] [14] In the case of cancer cells, exosomes may show differences in size, shape, morphology, and canonical markers from their donor cells. They may encapsulate relevant information that can be used for disease detection. [5] [7] Consequently, there is a growing interest in clinical applications of EVs as biomarkers and therapies alike, [15] prompting establishment of an International Society for Extracellular Vesicles (ISEV) and a scientific journal devoted to EVs, the Journal of Extracellular Vesicles .

Background

Exosomes were first discovered in the maturing mammalian reticulocyte (immature red blood cell) by Stahl and group in 1983 [16] and Johnstone and group in 1983 [17] further termed 'exosomes' by Johnstone and group in 1987. [18] Exosomes were shown to participate in selective removal of many plasma membrane proteins [19] as the reticulocyte becomes a mature red blood cell (erythrocyte). In the reticulocyte, as in most mammalian cells, portions of the plasma membrane are regularly internalized as endosomes, with 50 to 180% of the plasma membrane being recycled every hour. [20] In turn, parts of the membranes of some endosomes are subsequently internalized as smaller vesicles. Such endosomes are called multivesicular bodies because of their appearance, with many small vesicles, (ILVs or "intralumenal endosomal vesicles"), inside the larger body. The ILVs become exosomes if the MVB merges with the cell membrane, releasing the internal vesicles into the extracellular space. [21]

Exosomes contain various molecular constituents of their cell of origin, including proteins and RNA. Although the exosomal protein composition varies with the cell and tissue of origin, most exosomes contain an evolutionarily-conserved common set of protein molecules. The protein content of a single exosome, given certain assumptions of protein size and configuration, and packing parameters, can be about 20,000 molecules. [22] The cargo of mRNA and miRNA in exosomes was first discovered at the University of Gothenburg in Sweden. [23]

The content of exosomes changes depending on the cells of origin, and they thereby reflect their originating cells. Analysis of the dynamic variation of exosomes may provide a valuable means of monitoring diseases. [24] In that study, the differences in cellular and exosomal mRNA and miRNA content was described, as well as the functionality of the exosomal mRNA cargo. Exosomes have also been shown to carry double-stranded DNA. [25]

Exosomes can transfer molecules from one cell to another via membrane vesicle trafficking, thereby influencing the immune system, such as dendritic cells and B cells, and may play a functional role in mediating adaptive immune responses to pathogens and tumors. [26] [27] Therefore, scientists who are actively researching the role that exosomes may play in cell-to-cell signaling, often hypothesize that delivery of their cargo RNA molecules can explain biological effects. For example, mRNA in exosomes has been suggested to affect protein production in the recipient cell. [23] [28] [29] However, another study has suggested that miRNAs in exosomes secreted by mesenchymal stem cells (MSC) are predominantly pre- and not mature miRNAs. [30] Because the authors of this study did not find RNA-induced silencing complex-associated proteins in these exosomes, they suggested that only the pre-miRNAs, but not the mature miRNAs in MSC exosomes, have the potential to be biologically active in the recipient cells. Multiple mechanisms have been reported to be involved in loading miRNAs into exosomes, including specific motifs in the miRNA sequences, interactions with lncRNAs localized to the exosomes, interactions with RBPs, and post-translational modifications of Ago. [31]

Conversely, exosome production and content may be influenced by molecular signals received by the cell of origin. As evidence for this hypothesis, tumor cells exposed to hypoxia secrete exosomes with enhanced angiogenic and metastatic potential, suggesting that tumor cells adapt to a hypoxic microenvironment by secreting exosomes to stimulate angiogenesis or facilitate metastasis to more favorable environment. [32]

Terminology

Evolving consensus in the field is that the term "exosome" should be applied strictly to an EV of endosomal origin. Since it can be difficult to prove such an origin after an EV has left the cell, variations on the term "extracellular vesicle" are often appropriate instead. [2] [33]

Research

Exosomes from red blood cells contain the transferrin receptor that is absent in mature erythrocytes. Dendritic cell-derived exosomes express MHC I, MHC II, and costimulatory molecules and have been proven to be able to induce and enhance antigen-specific T cell responses in vivo. In addition, the first exosome-based cancer vaccination platforms are being explored in early clinical trials. [34] Exosomes can also be released into urine by the kidneys, and their detection might serve as a diagnostic tool. [35] [36] [37] Urinary exosomes may be useful as treatment response markers in prostate cancer. [38] [39] Exosomes secreted from tumour cells can deliver signals to surrounding cells and have been shown to regulate myofibroblast differentiation. [40] In melanoma, tumor-derived vesicles can enter lymphatics and interact with subcapsular sinus macrophages and B cells in lymph nodes. [41] A recent investigation showed that exosome release positively correlates with the invasiveness of ovarian cancer. [42] Exosomes released from tumors into the blood may also have diagnostic potential. Exosomes are remarkably stable in bodily fluids strengthening their utility as reservoirs for disease biomarkers. [43] [44] Patient blood samples stored in biorepositories can be used for biomarker analysis as colorectal cancer cell-derived exosomes spiked into blood plasma could be recovered after 90 days of storage at various temperatures. [45]

In malignancies such as cancer, the regulatory circuit that guards exosome homeostasis is co-opted to promote cancer cell survival and metastasis. [46] [29] In breast cancers, neratinib, a novel pan-ERBB inhibitor, is able to downmodulate the amount of HER2 released by exosomes, thus potentially reducing tumor dissemination. [47]

Urinary exosomes have also proven to be useful in the detection of many pathologies, such as genitourinary cancers and mineralocorticoid hypertension, through their protein and miRNA cargo." [48] [15]

With neurodegenerative disorders, exosomes appear to play a role in the spread of alpha-synuclein, and are being actively investigated as a tool to both monitor disease progression as well as a potential vehicle for delivery of drug and stem cell based therapy. [49]

An online open access database containing genomic information for exosome content has been developed to catalyze research development within the field. [49]

Exosomes and intercellular communication

Scientists are actively researching the role that exosomes may play in cell-to-cell signaling, hypothesizing that because exosomes can merge with and release their contents into cells that are distant from their cell of origin (see membrane vesicle trafficking), they may influence processes in the recipient cell. [50] For example, RNA that is shuttled from one cell to another, known as "exosomal shuttle RNA," could potentially affect protein production in the recipient cell. [28] [23] The role played by exosomes in cell-cell or interorgan communication and metabolic regulation was reviewed by Samuelson and Vidal-Puig in 2018. [51] By transferring molecules from one cell to another, exosomes from certain cells of the immune system, such as dendritic cells and B cells, may play a functional role in mediating adaptive immune responses to pathogens and tumors. [26] [41] Exosomal export of miRNA molecules is also linked to the arrest of inter cellular miRNA levels and affect their functionality by arresting them on heavy polysomes. [52]

Conversely, exosome production and content may be influenced by molecular signals received by the cell of origin. As evidence for this hypothesis, tumor cells exposed to hypoxia secrete exosomes with enhanced angiogenic and metastatic potential, suggesting that tumor cells adapt to a hypoxic microenvironment by secreting exosomes to stimulate angiogenesis or facilitate metastasis to more favorable environment. [32] It has recently been shown that exosomal protein content may change during the progression of chronic lymphocytic leukemia. [53]

A study hypothesized that intercellular communication of tumor exosomes could mediate further regions of metastasis for cancer. Hypothetically, exosomes can plant tumor information, such as tainted RNA, into new cells to prepare for cancer to travel to that organ for metastasis. The study found that tumor exosomal communication has the ability to mediate metastasis to different organs. Furthermore, even when tumor cells have a disadvantage for replicating, the information planted at these new regions, organs, can aid in the expansion of organ specific metastasis. [54]

Exosomes carry cargo, which can augment innate immune responses. For example, exosomes derived from Salmonella enterica-infected macrophages but not exosomes from uninfected cells stimulate naive macrophages and dendritic cells to secrete pro-inflammatory cytokines such as TNF-α, RANTES, IL-1ra, MIP-2, CXCL1, MCP-1, sICAM-1, GM-CSF, and G-CSF. Proinflammatory effects of exosomes are partially attributed to lipopolysaccharide, which is encapsulated within exosomes. [55]

Exosomes also mediate the cross talk between the embryo and maternal compartment during implantation.They help to exchange ubiquitous protein, glycoproteins, DNA and mRNA. [56]

Exosome biogenesis, secretion, and uptake

Exosomes biogenesis

Exosomes are extracellular vesicles having a unique biogenesis pathway via multivesicular bodies. Exosome kalamedits.jpg
Exosomes are extracellular vesicles having a unique biogenesis pathway via multivesicular bodies.

Exosome formation starts with the invagination of the multi-vesicular bodies (MVBs) or late endosomes to generate intraluminal vesicles (ILVs). [57] There are various proposed mechanisms for formation of MVBs, vesicle budding, and sorting. The most studied and well known is the endosomal sorting complex required for transport (ESCRT) dependent pathway. ESCRT machinery mediates the ubiquitinated pathway consisting of protein complexes; ESCRT-0, -I, -II, -III, and associated ATPase Vps4. ESCRT 0 recognizes and retains ubiquitinated proteins marked for packaging in the late endosomal membrane. ESCRT I/II recognizes the ESCRT 0 and starts creating involution of the membrane into the MVB. ESCRTIII forms a spiral-shaped structure constricting the neck. ATPase VPS4 protein drives the membrane scission. [58] Syndecan-syntenin-ALIX exosome biogenesis pathway are one of the ESCRT-independent or non-canonical pathways for exosome biogenesis. [59]

Exosome secretion

The MVBs once formed are trafficked to the internal side of the plasma membrane. These MVBs are transported to the plasma membrane leading to fusion. [57] Many studies have shown that MVBs having higher cholesterol content fuse with the plasma membrane thus releasing exosomes. [60] The Rab proteins especially Rab 7 attached to the MVB recognizes its effector receptor. The SNARE complex (soluble N- ethylmaleimide- sensitive fusion attachment protein receptor) from the MVB and the plasma membrane interacts and mediates fusion.

Exosome uptake

Specific targeting by exosomes is an active area of research. The exact mechanisms of exosome targeting is limited to a few general mechanisms like docking of the exosomes with specific proteins, sugars, and lipid, or micropinocytosis. The internalized exosomes are targeted to the endosomes which release their content in the recipient cell. [61] [62]

Sorting and packaging of cargoes in exosomes

Exosomes contain different cargoes; proteins, lipids, and nucleic acids. These cargoes are specifically sorted and packaged into exosomes. The contents packaged into exosomes are cell type specific and also influenced by cellular conditions. [57] Exosomal microRNAs (exomiRs) and proteins are sorted and packaged in exosomes. Villarroya-Beltri and colleagues identified a conserved GGAG specific motif, EXOmotif, in the miRNA packaged in the exosomes which was absent in the cytosolic miRNA (CLmiRNA), which binds to sumoylated heterogeneous nuclear riboprotein (hnRNP) A2B1 for exosome specific miRNA packaging [63] Proteins are packaged in ESCRT, tertraspanins, lipid- dependent mechanisms. [64] Exosomes are enriched in cholesterol, sphingomyelin, saturated phosphatidylcholine and phosphatidylethanolamine as compared to the plasma membrane of the cell. [64]

Isolation

The isolation and detection of exosomes has proven to be complicated. [6] [65] Due to the complexity of body fluids, physical separation of exosomes from cells and similar-sized particles is challenging. Isolation of exosomes using differential ultracentrifugation results in co-isolation of protein and other contaminants and incomplete separation of vesicles from lipoproteins. [66] Combining ultracentrifugation with micro-filtration or a gradient can improve purity. [67] [68] Single step isolation of extracellular vesicles by size-exclusion chromatography has been demonstrated to provide greater efficiency for recovering intact vesicles over centrifugation, [69] although a size-based technique alone will not be able to distinguish exosomes from other vesicle types. [70] To isolate a pure population of exosomes a combination of techniques is necessary, based on both physical (e.g. size, density) and biochemical parameters (e.g. presence/absence of certain proteins involved in their biogenesis). [66] [71] The use of reference materials such as trackable recombinant EV will assist in mitigating technical variation introduced during sample preparation and analysis. [72] [73] Novel selective isolation methodology has been using a combination of immunoaffinity chromatography and asymmetric-flow field-flow fractionation to reduce the contamination from lipoproteins and other proteins when isolating from blood plasma. [74] [75]

Often, functional as well as antigenic assays are applied to derive useful information from multiple exosomes. Well-known examples of assays to detect proteins in total populations of exosomes are mass spectrometry and Western blot. However, a limitation of these methods is that contaminants may be present that affect the information obtained from such assays. Preferably, information is derived from single exosomes. Relevant properties of exosomes to detect include size, density, morphology, composition, and zeta potential. [76]

Detection

Since the diameter of exosomes is typically below 100 nm and because they have a low refractive index, exosomes are below the detection range of many currently used techniques. A number of miniaturized systems, exploiting nanotechnology and microfluidics, have been developed to expedite exosome analyses. These new systems include a microNMR device, [77] a nanoplasmonic chip, [78] and a magneto-electrochemical sensor [79] for protein profiling; and an integrated fluidic cartridge for RNA detection. [80] Flow cytometry is an optical method to detect exosomes in suspension. Nevertheless, the applicability of flow cytometry to detect single exosomes is still inadequate due to limited sensitivity and potential measurement artifacts such as swarm detection. [81] Other methods to detect single exosomes are atomic force microscopy, [82] nanoparticle tracking analysis, [83] Raman microspectroscopy, [84] tunable resistive pulse sensing, and transmission electron microscopy. [81] [47]

Bioinformatics analysis

Exosomes contain RNA, proteins, lipids and metabolites that is reflective of the cell type of origin. As exosomes contain numerous proteins, RNA and lipids, large scale analysis including proteomics and transcriptomics is often performed. Currently, to analyse these data, non-commercial tools such as FunRich [85] can be used to identify over-represented groups of molecules. With the advent of Next generation sequencing technologies, the research on exosomes have been accelerated in not only cancer but various diseases. Recently, bioinformatics based analysis of RNA-Seq data of exosomes extracted from Trypanosoma cruzi has showed the association of these extracellular vesicles with various important gene products that strengthens the probability of finding biomarkers for Chagas disease. [86]

Therapeutics and carriers of drugs

Increasingly, exosomes are being recognized as potential therapeutics as they have the ability to elicit potent cellular responses in vitro and in vivo. [87] [88] [89] Exosomes mediate regenerative outcomes in injury and disease that recapitulate observed bioactivity of stem cell populations. [90] [91] Mesenchymal stem cell exosomes were found to activate several signaling pathways important in wound healing (Akt, ERK, and STAT3), bone fracture repair [92] [93] and participates in the regulation of immune-mediated responses [94] [95] and inflammatory diseases. [96] [97] They induce the expression of a number of growth factors (hepatocyte growth factor (HGF), insulin-like growth factor-1 (IGF1), nerve growth factor (NGF), and stromal-derived growth factor-1 (SDF1)). [98] Exosomes secreted by human circulating fibrocytes, a population of mesenchymal progenitors involved in normal wound healing via paracrine signaling, exhibited in-vitro proangiogenic properties, activated diabetic dermal fibroblasts, induced the migration and proliferation of diabetic keratinocytes, and accelerated wound closure in diabetic mice in vivo. Important components of the exosomal cargo were heat shock protein-90α, total and activated signal transducer and activator of transcription 3, proangiogenic (miR-126, miR-130a, miR-132) and anti-inflammatory (miR124a, miR-125b) microRNAs, and a microRNA regulating collagen deposition (miR-21). [99] Researchers have also found that exosomes released from oral keratinocytes can accelerate wound healing, even when human exosomes were applied to rat wounds. [100] Exosomes can be considered a promising carrier for effective delivery of small interfering RNA due to their existence in body's endogenous system and high tolerance. [101] [102] Patient-derived exosomes have been employed as a novel cancer immunotherapy in several clinical trials. [103]

Exosome-mediated delivery of superoxide dismutase extends life-span in Caenorhabditis elegans , apparently by reducing the level of reactive oxygen species. [104] Thus this system is being studied for its anti-aging potential. [104] This delivery system also improved survival under conditions of oxidative stress and heat. [104]

Exosomes offer distinct advantages that uniquely position them as highly effective drug carriers. [105] Composed of cellular membranes with multiple adhesive proteins on their surface, exosomes are known to specialize in cell–cell communications and provide an exclusive approach for the delivery of various therapeutic agents to target cells. [106] For example, researchers used exosomes as a vehicle for the delivery of cancer drug paclitaxel. They placed the drug inside exosomes derived from white blood cells, which were then injected into mice with drug-resistant lung cancer. Importantly, incorporation of paclitaxel into exosomes increased cytotoxicity more than 50 times as a result of nearly complete co-localization of airway-delivered exosomes with lung cancer cells. [107]

Unapproved marketing

Different forms of unproven exosomes are being marketed in the U.S. for a wide variety of health conditions by clinic firms, without authorization from the FDA. Often, these firms also sell non-FDA-approved stem cell injections as well. In late 2019, the FDA issued an advisory warning about noncompliant marketing of exosomes and injuries to patients in Nebraska related to injections of exosomes. [108] The agency also indicated that exosomes are officially drug products requiring pre-market approval. In 2020, the FDA cautioned several firms about marketing or use of exosomes for COVID-19 and other health conditions. [109] [110] [111]

See also

Related Research Articles

<span class="mw-page-title-main">Endocytosis</span> Cellular process

Endocytosis is a cellular process in which substances are brought into the cell. The material to be internalized is surrounded by an area of cell membrane, which then buds off inside the cell to form a vesicle containing the ingested materials. Endocytosis includes pinocytosis and phagocytosis. It is a form of active transport.

<span class="mw-page-title-main">Vesicle (biology and chemistry)</span> Any small, fluid-filled, spherical organelle enclosed by a membrane

In cell biology, a vesicle is a structure within or outside a cell, consisting of liquid or cytoplasm enclosed by a lipid bilayer. Vesicles form naturally during the processes of secretion (exocytosis), uptake (endocytosis), and the transport of materials within the plasma membrane. Alternatively, they may be prepared artificially, in which case they are called liposomes. If there is only one phospholipid bilayer, the vesicles are called unilamellar liposomes; otherwise they are called multilamellar liposomes. The membrane enclosing the vesicle is also a lamellar phase, similar to that of the plasma membrane, and intracellular vesicles can fuse with the plasma membrane to release their contents outside the cell. Vesicles can also fuse with other organelles within the cell. A vesicle released from the cell is known as an extracellular vesicle.

Heat shock proteins (HSPs) are a family of proteins produced by cells in response to exposure to stressful conditions. They were first described in relation to heat shock, but are now known to also be expressed during other stresses including exposure to cold, UV light and during wound healing or tissue remodeling. Many members of this group perform chaperone functions by stabilizing new proteins to ensure correct folding or by helping to refold proteins that were damaged by the cell stress. This increase in expression is transcriptionally regulated. The dramatic upregulation of the heat shock proteins is a key part of the heat shock response and is induced primarily by heat shock factor (HSF). HSPs are found in virtually all living organisms, from bacteria to humans.

<span class="mw-page-title-main">Endosome</span> Vacuole to which materials ingested by endocytosis are delivered

Endosomes are a collection of intracellular sorting organelles in eukaryotic cells. They are parts of endocytic membrane transport pathway originating from the trans Golgi network. Molecules or ligands internalized from the plasma membrane can follow this pathway all the way to lysosomes for degradation or can be recycled back to the cell membrane in the endocytic cycle. Molecules are also transported to endosomes from the trans Golgi network and either continue to lysosomes or recycle back to the Golgi apparatus.

The epithelial–mesenchymal transition (EMT) is a process by which epithelial cells lose their cell polarity and cell–cell adhesion, and gain migratory and invasive properties to become mesenchymal stem cells; these are multipotent stromal cells that can differentiate into a variety of cell types. EMT is essential for numerous developmental processes including mesoderm formation and neural tube formation. EMT has also been shown to occur in wound healing, in organ fibrosis and in the initiation of metastasis in cancer progression.

<span class="mw-page-title-main">Adrenal tumor</span> Medical condition

An adrenal tumor or adrenal mass is any benign or malignant neoplasms of the adrenal gland, several of which are notable for their tendency to overproduce endocrine hormones. Adrenal cancer is the presence of malignant adrenal tumors, and includes neuroblastoma, adrenocortical carcinoma and some adrenal pheochromocytomas. Most adrenal pheochromocytomas and all adrenocortical adenomas are benign tumors, which do not metastasize or invade nearby tissues, but may cause significant health problems by unbalancing hormones.

<span class="mw-page-title-main">Microvesicle</span> Type of extracellular vesicle

Microvesicles are a type of extracellular vesicle (EV) that are released from the cell membrane. In multicellular organisms, microvesicles and other EVs are found both in tissues and in many types of body fluids. Delimited by a phospholipid bilayer, microvesicles can be as small as the smallest EVs or as large as 1000 nm. They are considered to be larger, on average, than intracellularly-generated EVs known as exosomes. Microvesicles play a role in intercellular communication and can transport molecules such as mRNA, miRNA, and proteins between cells.

<span class="mw-page-title-main">CD9</span> Human protein-encoding gene

CD9 is a gene encoding a protein that is a member of the transmembrane 4 superfamily also known as the tetraspanin family. It is a cell surface glycoprotein that consists of four transmembrane regions and has two extracellular loops that contain disulfide bonds which are conserved throughout the tetraspanin family. Also containing distinct palmitoylation sites that allows CD9 to interact with lipids and other proteins.

<span class="mw-page-title-main">TSG101</span> Protein-coding gene in the species Homo sapiens

Tumor susceptibility gene 101, also known as TSG101, is a human gene that encodes for a cellular protein of the same name.

<span class="mw-page-title-main">Epithelial cell adhesion molecule</span> Transmembrane glycoprotein

Epithelial cell adhesion molecule (EpCAM), also known as CD326 among other names, is a transmembrane glycoprotein mediating Ca2+-independent homotypic cell–cell adhesion in epithelia. EpCAM is also involved in cell signaling, migration, proliferation, and differentiation. Additionally, EpCAM has oncogenic potential via its capacity to upregulate c-myc, e-fabp, and cyclins A & E. Since EpCAM is expressed exclusively in epithelia and epithelial-derived neoplasms, EpCAM can be used as diagnostic marker for various cancers. It appears to play a role in tumorigenesis and metastasis of carcinomas, so it can also act as a potential prognostic marker and as a potential target for immunotherapeutic strategies.

The endosomal sorting complexes required for transport (ESCRT) machinery is made up of cytosolic protein complexes, known as ESCRT-0, ESCRT-I, ESCRT-II, and ESCRT-III. Together with a number of accessory proteins, these ESCRT complexes enable a unique mode of membrane remodeling that results in membranes bending/budding away from the cytoplasm. These ESCRT components have been isolated and studied in a number of organisms including yeast and humans. A eukaryotic signature protein, the machinery is found in all eukaryotes and some archaea.

ExoCarta is a manually curated database of exosomal proteins, RNA and lipids.

mir-200

In molecular biology, the miR-200 microRNA is a short RNA molecule. MicroRNAs function to regulate the expression levels of other genes by binding and cleaving mRNAs or inhibiting translation. The miR-200 family contains miR-200a, miR-200b, miR-200c, miR-141, and miR-429. There is growing evidence to suggest that miR-200 microRNAs are involved in cancer metastasis.

Jan Lötvall is a Swedish clinical allergist and scientist working on translational research primarily in the field of asthma. He is the former director of the Krefting Research Centre at the University of Gothenburg and is the Chief Scientific Officer of ExoCoBio.

Extracellular RNA (exRNA) describes RNA species present outside of the cells in which they were transcribed. Carried within extracellular vesicles, lipoproteins, and protein complexes, exRNAs are protected from ubiquitous RNA-degrading enzymes. exRNAs may be found in the environment or, in multicellular organisms, within the tissues or biological fluids such as venous blood, saliva, breast milk, urine, semen, menstrual blood, and vaginal fluid. Although their biological function is not fully understood, exRNAs have been proposed to play a role in a variety of biological processes including syntrophy, intercellular communication, and cell regulation. The United States National Institutes of Health (NIH) published in 2012 a set of Requests for Applications (RFAs) for investigating extracellular RNA biology. Funded by the NIH Common Fund, the resulting program was collectively known as the Extracellular RNA Communication Consortium (ERCC). The ERCC was renewed for a second phase in 2019.

<span class="mw-page-title-main">Tumor microenvironment</span> Surroundings of tumors including nearby cells and blood vessels

The tumor microenvironment is a complex ecosystem surrounding a tumor, composed of cancer cells, stromal tissue and the extracellular matrix. Mutual interaction between cancer cells and the different components of the tumor microenvironment support its growth and invasion in healthy tissues which correlates with tumor resistance to current treatments and poor prognosis. The tumor microenvironment is in constant change because of the tumor's ability to influence the microenvironment by releasing extracellular signals, promoting tumor angiogenesis and inducing peripheral immune tolerance, while the immune cells in the microenvironment can affect the growth and evolution of cancerous cells.

The secretome is the set of proteins expressed by an organism and secreted into the extracellular space. In humans, this subset of the proteome encompasses 13-20% of all proteins, including cytokines, growth factors, extracellular matrix proteins and regulators, and shed receptors. The secretome of a specific tissue can be measured by mass spectrometry and its analysis constitutes a type of proteomics known as secretomics.

Extracellular vesicles (EVs) are lipid bilayer-delimited particles that are naturally released from almost all types of cells but, unlike a cell, cannot replicate. EVs range in diameter from near the size of the smallest physically possible unilamellar liposome to as large as 10 microns or more, although the vast majority of EVs are smaller than 200 nm. EVs can be divided according to size and synthesis route into exosomes, microvesicles and apoptotic bodies. The composition of EVs varies depending on their parent cells, encompassing proteins, lipids, nucleic acids, metabolites, and even organelles. Most cells that have been studied to date are thought to release EVs, including some archaeal, bacterial, fungal, and plant cells that are surrounded by cell walls. A wide variety of EV subtypes have been proposed, defined variously by size, biogenesis pathway, cargo, cellular source, and function, leading to a historically heterogenous nomenclature including terms like exosomes and ectosomes.

The stem cell secretome is a collective term for the paracrine soluble factors produced by stem cells and utilized for their inter-cell communication. In addition to inter-cell communication, the paracrine factors are also responsible for tissue development, homeostasis and (re-)generation. The stem cell secretome consists of extracellular vesicles, specifically exosomes, microvesicles, membrane particles, peptides and small proteins (cytokines). The paracrine activity of stem cells, i.e. the stem cell secretome, has been found to be the predominant mechanism by which stem cell-based therapies mediate their effects in degenerative, auto-immune and/or inflammatory diseases. Though not only stem cells possess a secretome which influences their cellular environment, their secretome currently appears to be the most relevant for therapeutic use.

Exosomes are small vesicles secreted by cells that play a crucial role in intercellular communication. They contain a variety of biomolecules, including proteins, nucleic acids and lipids, which can be transferred between cells to modulate cellular processes. Exosomes have been increasingly acknowledged as promising therapeutic tool and delivery platforms due to unique biological properties.

  1. Biocompatibility: Exosomes are naturally occurring particles in body, which makes them highly biocompatible and less likely to activate immune response.
  2. Targeting ability: Exosomes are assembled to express specific proteins or peptides, allowing them to target specific cells or tissues.
  3. Natural cargo carries: Exosomes can naturally transport a variety of biomolecules, including proteins, RNA and DNA, which can be used for therapeutic purposes.

References

  1. ↑ Moghassemi S, Dadashzadeh A, Sousa MJ, Vlieghe H, Yang J, León-Félix CM, Amorim CA (June 2024). "Extracellular vesicles in nanomedicine and regenerative medicine: A review over the last decade". Bioactive Materials. 36: 126–156. doi:10.1016/j.bioactmat.2024.02.021. PMC   10915394 . PMID   38450204.
  2. 1 2 3 Théry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, metal (2018). "Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines". Journal of Extracellular Vesicles. 7 (1): 1535750. doi:10.1080/20013078.2018.1535750. PMC   6322352 . PMID   30637094.
  3. ↑ Yáñez-Mó M, Siljander PR, Andreu Z, Zavec AB, Borràs FE, Buzas EI, metal (2015). "Biological properties of extracellular vesicles and their physiological functions". Journal of Extracellular Vesicles. 4: 27066. doi:10.3402/jev.v4.27066. PMC   4433489 . PMID   25979354.
  4. ↑ van Niel G, D'Angelo G, Raposo G (April 2018). "Shedding light on the cell biology of extracellular vesicles" (PDF). Nature Reviews. Molecular Cell Biology. 19 (4): 213–228. doi:10.1038/nrm.2017.125. PMID   29339798. S2CID   3944339.
  5. 1 2 3 Nonaka T, Wong D (13 June 2022). "Saliva Diagnostics". Annual Review of Analytical Chemistry. 15 (1): 107–121. Bibcode:2022ARAC...15..107N. doi:10.1146/annurev-anchem-061020-123959. PMC   9348814 . PMID   35696523.
  6. 1 2 3 4 5 van der Pol E, Böing AN, Harrison P, Sturk A, Nieuwland R (July 2012). "Classification, functions, and clinical relevance of extracellular vesicles". Pharmacological Reviews. 64 (3): 676–705. doi:10.1124/pr.112.005983. PMID   22722893. S2CID   7764903.
  7. 1 2 3 Chen TY, Gonzalez-Kozlova E, Soleymani T, La Salvia S, Kyprianou N, Sahoo S, Tewari AK, Cordon-Cardo C, Stolovitzky G, Dogra N (17 June 2022). "Extracellular vesicles carry distinct proteo-transcriptomic signatures that are different from their cancer cell of origin". iScience. 25 (6): 104414. Bibcode:2022iSci...25j4414C. doi:10.1016/j.isci.2022.104414. ISSN   2589-0042. PMC   9157216 . PMID   35663013.
  8. ↑ Janas AM, Sapoń K, Janas T, Stowell MH, Janas T (June 2016). "Exosomes and other extracellular vesicles in neural cells and neurodegenerative diseases". Biochimica et Biophysica Acta (BBA) - Biomembranes. 1858 (6): 1139–51. doi: 10.1016/j.bbamem.2016.02.011 . PMID   26874206.
  9. ↑ Huleihel L, Hussey GS, Naranjo JD, Zhang L, Dziki JL, Turner NJ, et al. (June 2016). "Matrix-bound nanovesicles within ECM bioscaffolds". Science Advances. 2 (6): e1600502. Bibcode:2016SciA....2E0502H. doi:10.1126/sciadv.1600502. PMC   4928894 . PMID   27386584.
  10. ↑ Keller S, Sanderson MP, Stoeck A, Altevogt P (November 2006). "Exosomes: from biogenesis and secretion to biological function". Immunology Letters. 107 (2): 102–8. doi:10.1016/j.imlet.2006.09.005. PMID   17067686.
  11. ↑ Spaull R, McPherson B, Gialeli A, Clayton A, Uney J, Heep A, Cordero-Llana Ó (April 2019). "Exosomes populate the cerebrospinal fluid of preterm infants with post-haemorrhagic hydrocephalus" (PDF). International Journal of Developmental Neuroscience. 73: 59–65. doi:10.1016/j.ijdevneu.2019.01.004. PMID   30639393. S2CID   58561998.
  12. ↑ Moghassemi S, Dadashzadeh A, Sousa MJ, Vlieghe H, Yang J, León-Félix CM, Amorim CA (June 2024). "Extracellular vesicles in nanomedicine and regenerative medicine: A review over the last decade". Bioactive Materials. 36: 126–156. doi:10.1016/j.bioactmat.2024.02.021. PMC   10915394 . PMID   38450204.
  13. ↑ Rudraprasad D, Rawat A, Joseph J (2022-01-01). "Exosomes, extracellular vesicles and the eye". Experimental Eye Research. 214: 108892. doi:10.1016/j.exer.2021.108892. ISSN   0014-4835. PMID   34896308. S2CID   245028439.
  14. ↑ Loewy MA (14 March 2023). "Saliva: The next frontier in cancer detection". Knowable Magazine | Annual Reviews. doi: 10.1146/knowable-031323-1 . S2CID   257541737.
  15. 1 2 Dhondt B, Van Deun J, Vermaerke S, de Marco A, Lumen N, De Wever O, Hendrix A (June 2018). "Urinary extracellular vesicle biomarkers in urological cancers: From discovery towards clinical implementation". The International Journal of Biochemistry & Cell Biology. 99: 236–256. doi:10.1016/j.biocel.2018.04.009. PMID   29654900. S2CID   4876604.
  16. ↑ Harding C, Stahl P (June 1983). "Transferrin recycling in reticulocytes: pH and iron are important determinants of ligand binding and processing". Biochemical and Biophysical Research Communications. 113 (2): 650–8. doi:10.1016/0006-291X(83)91776-X. PMID   6870878.
  17. ↑ Pan BT, Johnstone RM (July 1983). "Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor". Cell. 33 (3): 967–78. doi:10.1016/0092-8674(83)90040-5. PMID   6307529. S2CID   33216388.
  18. ↑ Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C (July 1987). "Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes)". The Journal of Biological Chemistry. 262 (19): 9412–20. doi: 10.1016/S0021-9258(18)48095-7 . PMID   3597417.
  19. ↑ van Niel G, Porto-Carreiro I, Simoes S, Raposo G (July 2006). "Exosomes: a common pathway for a specialized function". Journal of Biochemistry. 140 (1): 13–21. doi: 10.1093/jb/mvj128 . PMID   16877764. S2CID   43541754.
  20. ↑ Huotari J, Helenius A (August 2011). "Endosome maturation". The EMBO Journal. 30 (17): 3481–500. doi:10.1038/emboj.2011.286. PMC   3181477 . PMID   21878991.
  21. ↑ Gruenberg J, van der Goot FG (July 2006). "Mechanisms of pathogen entry through the endosomal compartments". Nature Reviews. Molecular Cell Biology. 7 (7): 495–504. doi:10.1038/nrm1959. PMID   16773132. S2CID   429568.
  22. ↑ Maguire, Greg (2016) Exosomes: smart nanospheres for drug delivery naturally produced by stem cells. In: Fabrication and Self Assembly of Nanobiomaterials. Elsevier pp. 179-209.
  23. 1 2 3 Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO (June 2007). "Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells". Nature Cell Biology. 9 (6): 654–9. doi:10.1038/ncb1596. PMID   17486113. S2CID   8599814.
  24. ↑ Nuzhat Z, Kinhal V, Sharma S, Rice GE, Joshi V, Salomon C (March 2017). "Tumour-derived exosomes as a signature of pancreatic cancer - liquid biopsies as indicators of tumour progression". Oncotarget. 8 (10): 17279–17291. doi:10.18632/oncotarget.13973. PMC   5370040 . PMID   27999198.
  25. ↑ Thakur BK, Zhang H, Becker A, Matei I, Huang Y, Costa-Silva B, et al. (June 2014). "Double-stranded DNA in exosomes: a novel biomarker in cancer detection". Cell Research. 24 (6): 766–9. doi:10.1038/cr.2014.44. PMC   4042169 . PMID   24710597.
  26. 1 2 Li XB, Zhang ZR, Schluesener HJ, Xu SQ (2006). "Role of exosomes in immune regulation". Journal of Cellular and Molecular Medicine. 10 (2): 364–75. doi:10.1111/j.1582-4934.2006.tb00405.x. PMC   3933127 . PMID   16796805.
  27. ↑ Hough KP, Chanda D, Duncan SR, Thannickal VJ, Deshane JS (April 2017). "Exosomes in immunoregulation of chronic lung diseases". Allergy. 72 (4): 534–544. doi:10.1111/all.13086. PMC   5462600 . PMID   27859351.
  28. 1 2 Balaj L, Lessard R, Dai L, Cho YJ, Pomeroy SL, Breakefield XO, Skog J (February 2011). "Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences". Nature Communications. 2 (2): 180. Bibcode:2011NatCo...2..180B. doi:10.1038/ncomms1180. PMC   3040683 . PMID   21285958.
  29. 1 2 Oushy S, Hellwinkel JE, Wang M, Nguyen GJ, Gunaydin D, Harland TA, et al. (January 2018). "Glioblastoma multiforme-derived extracellular vesicles drive normal astrocytes towards a tumour-enhancing phenotype". Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 373 (1737): 20160477. doi:10.1098/rstb.2016.0477. PMC   5717433 . PMID   29158308.
  30. ↑ Chen TS, Lai RC, Lee MM, Choo AB, Lee CN, Lim SK (January 2010). "Mesenchymal stem cell secretes microparticles enriched in pre-microRNAs". Nucleic Acids Research. 38 (1): 215–24. doi:10.1093/nar/gkp857. PMC   2800221 . PMID   19850715.
  31. ↑ Gebert LF, MacRae IJ (January 2019). "Regulation of microRNA function in animals". Nature Reviews. Molecular Cell Biology. 20 (1): 21–37. doi:10.1038/s41580-018-0045-7. PMC   6546304 . PMID   30108335.
  32. 1 2 Park JE, Tan HS, Datta A, Lai RC, Zhang H, Meng W, et al. (June 2010). "Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes". Molecular & Cellular Proteomics. 9 (6): 1085–99. doi: 10.1074/mcp.M900381-MCP200 . PMC   2877972 . PMID   20124223.
  33. ↑ Witwer KW, Théry C (2019). "Extracellular vesicles or exosomes? On primacy, precision, and popularity influencing a choice of nomenclature". Journal of Extracellular Vesicles. 8 (1): 1648167. doi:10.1080/20013078.2019.1648167. PMC   6711079 . PMID   31489144.
  34. ↑ Mignot G, Roux S, Thery C, Ségura E, Zitvogel L (2006). "Prospects for exosomes in immunotherapy of cancer". Journal of Cellular and Molecular Medicine. 10 (2): 376–88. doi:10.1111/j.1582-4934.2006.tb00406.x. PMC   3933128 . PMID   16796806.
  35. ↑ Pisitkun T, Shen RF, Knepper MA (September 2004). "Identification and proteomic profiling of exosomes in human urine". Proceedings of the National Academy of Sciences of the United States of America. 101 (36): 13368–73. Bibcode:2004PNAS..10113368P. doi: 10.1073/pnas.0403453101 . PMC   516573 . PMID   15326289.
  36. ↑ "Urinary Exosome Protein Database". NHLBI. 2009-05-12. Retrieved 2009-10-01.
  37. ↑ Nilsson J, Skog J, Nordstrand A, Baranov V, Mincheva-Nilsson L, Breakefield XO, Widmark A (May 2009). "Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer". British Journal of Cancer. 100 (10): 1603–7. doi:10.1038/sj.bjc.6605058. PMC   2696767 . PMID   19401683.
  38. ↑ "Fat capsules carry markers for deadly prostate cancer". The Medical News. 2009-05-13. Retrieved 2009-10-01.
  39. ↑ Mitchell PJ, Welton J, Staffurth J, Court J, Mason MD, Tabi Z, Clayton A (January 2009). "Can urinary exosomes act as treatment response markers in prostate cancer?". Journal of Translational Medicine. 7 (1): 4. doi: 10.1186/1479-5876-7-4 . PMC   2631476 . PMID   19138409.
  40. ↑ Webber J, Steadman R, Mason MD, Tabi Z, Clayton A (December 2010). "Cancer exosomes trigger fibroblast to myofibroblast differentiation". Cancer Research. 70 (23): 9621–30. doi: 10.1158/0008-5472.CAN-10-1722 . PMID   21098712.
  41. 1 2 Pucci F, Garris C, Lai CP, Newton A, Pfirschke C, Engblom C, et al. (April 2016). "SCS macrophages suppress melanoma by restricting tumor-derived vesicle-B cell interactions". Science. 352 (6282): 242–6. Bibcode:2016Sci...352..242P. doi:10.1126/science.aaf1328. PMC   4960636 . PMID   26989197.
  42. ↑ Kobayashi M, Salomon C, Tapia J, Illanes SE, Mitchell MD, Rice GE (January 2014). "Ovarian cancer cell invasiveness is associated with discordant exosomal sequestration of Let-7 miRNA and miR-200". Journal of Translational Medicine. 12: 4. doi: 10.1186/1479-5876-12-4 . PMC   3896684 . PMID   24393345.
  43. ↑ Williams C, Royo F, Aizpurua-Olaizola O, Pazos R, Boons GJ, Reichardt NC, Falcon-Perez JM (2018). "Glycosylation of extracellular vesicles: current knowledge, tools and clinical perspectives". Journal of Extracellular Vesicles. 7 (1): 1442985. doi:10.1080/20013078.2018.1442985. PMC   5844028 . PMID   29535851.
  44. ↑ Aizpurua-Olaizola O, Toraño JS, Falcon-Perez JM, Williams C, Reichardt N, Boons GJ (2018). "Mass spectrometry for glycan biomarker discovery". TrAC Trends in Analytical Chemistry. 100: 7–14. doi:10.1016/j.trac.2017.12.015. hdl:1874/364403.
  45. ↑ Kalra H, Adda CG, Liem M, Ang CS, Mechler A, Simpson RJ, et al. (November 2013). "Comparative proteomics evaluation of plasma exosome isolation techniques and assessment of the stability of exosomes in normal human blood plasma". Proteomics. 13 (22): 3354–64. doi:10.1002/pmic.201300282. PMID   24115447. S2CID   45991971.
  46. ↑ Syn N, Wang L, Sethi G, Thiery JP, Goh BC (July 2016). "Exosome-Mediated Metastasis: From Epithelial-Mesenchymal Transition to Escape from Immunosurveillance". Trends in Pharmacological Sciences. 37 (7): 606–617. doi:10.1016/j.tips.2016.04.006. PMID   27157716.
  47. 1 2 Santamaria S, Gagliani MC, Bellese G, Marconi S, Lechiara A, Dameri M, et al. (July 2021). "Imaging of Endocytic Trafficking and Extracellular Vesicles Released Under Neratinib Treatment in ERBB2+ Breast Cancer Cells". The Journal of Histochemistry and Cytochemistry. 69 (7): 461–473. doi:10.1369/00221554211026297. PMC   8246527 . PMID   34126793.
  48. ↑ Barros ER, Carvajal CA (2017-09-08). "Urinary Exosomes and Their Cargo: Potential Biomarkers for Mineralocorticoid Arterial Hypertension?". Frontiers in Endocrinology. 8: 230. doi: 10.3389/fendo.2017.00230 . PMC   5599782 . PMID   28951728.
  49. 1 2 Tofaris GK (2017). "A Critical Assessment of Exosomes in the Pathogenesis and Stratification of Parkinson's Disease". Journal of Parkinson's Disease. 7 (4): 569–576. doi:10.3233/JPD-171176. PMC   5676982 . PMID   28922170.
  50. ↑ Dhondt B, Rousseau Q, De Wever O, Hendrix A (September 2016). "Function of extracellular vesicle-associated miRNAs in metastasis". Cell and Tissue Research. 365 (3): 621–41. doi:10.1007/s00441-016-2430-x. hdl:1854/LU-7250365. PMID   27289232. S2CID   2746182.
  51. ↑ Samuelson I, Vidal-Puig AJ (May 2018). "Fed-EXosome: extracellular vesicles and cell-cell communication in metabolic regulation". Essays in Biochemistry. 62 (2): 165–175. doi: 10.1042/EBC20170087 . PMID   29717059.
  52. ↑ Ghosh S, Bose M, Ray A, Bhattacharyya SN (March 2015). "Polysome arrest restricts miRNA turnover by preventing exosomal export of miRNA in growth-retarded mammalian cells". Molecular Biology of the Cell. 26 (6): 1072–83. doi:10.1091/mbc.E14-11-1521. PMC   4357507 . PMID   25609084.
  53. ↑ Prieto D, Sotelo N, Seija N, Sernbo S, Abreu C, Durán R, et al. (August 2017). "S100-A9 protein in exosomes from chronic lymphocytic leukemia cells promotes NF-κB activity during disease progression". Blood. 130 (6): 777–788. doi: 10.1182/blood-2017-02-769851 . hdl: 20.500.12008/31377 . PMID   28596424.
  54. ↑ Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M, et al. (November 2015). "Tumour exosome integrins determine organotropic metastasis". Nature. 527 (7578): 329–35. Bibcode:2015Natur.527..329H. doi:10.1038/nature15756. PMC   4788391 . PMID   26524530.
  55. ↑ Hui WW, Hercik K, Belsare S, Alugubelly N, Clapp B, Rinaldi C, Edelmann MJ (February 2018). "Salmonella enterica Serovar Typhimurium Alters the Extracellular Proteome of Macrophages and Leads to the Production of Proinflammatory Exosomes". Infection and Immunity. 86 (2): e00386–17. doi:10.1128/IAI.00386-17. PMC   5778363 . PMID   29158431.
  56. ↑ Kurian NK, Modi D (2019). "Extracellular vesicle mediated embryo-endometrial cross talk during implantation and in pregnancy". Journal of Assisted Reproduction and Genetics. 36 (2): 189–198. doi:10.1007/s10815-018-1343-x. PMC   6420537 . PMID   30362057.
  57. 1 2 3 Hessvik NP, Llorente A (January 2018). "Current knowledge on exosome biogenesis and release". Cellular and Molecular Life Sciences. 75 (2): 193–208. doi:10.1007/s00018-017-2595-9. PMC   5756260 . PMID   28733901.
  58. ↑ Wollert T, Hurley JH (April 2010). "Molecular mechanism of multivesicular body biogenesis by ESCRT complexes". Nature. 464 (7290): 864–9. Bibcode:2010Natur.464..864W. doi:10.1038/nature08849. PMC   2851844 . PMID   20305637.
  59. ↑ Baietti MF, Zhang Z, Mortier E, Melchior A, Degeest G, Geeraerts A, et al. (June 2012). "Syndecan-syntenin-ALIX regulates the biogenesis of exosomes". Nature Cell Biology. 14 (7): 677–85. doi:10.1038/ncb2502. PMID   22660413. S2CID   30598897.
  60. ↑ Möbius W, Ohno-Iwashita Y, van Donselaar EG, Oorschot VM, Shimada Y, Fujimoto T, et al. (January 2002). "Immunoelectron microscopic localization of cholesterol using biotinylated and non-cytolytic perfringolysin O". The Journal of Histochemistry and Cytochemistry. 50 (1): 43–55. doi: 10.1177/002215540205000105 . PMID   11748293.
  61. ↑ Mathieu M, Martin-Jaular L, Lavieu G, Théry C (January 2019). "Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication". Nature Cell Biology. 21 (1): 9–17. doi:10.1038/s41556-018-0250-9. PMID   30602770. S2CID   57373483.
  62. ↑ Shirazi S, Huang CC, Kang M, Lu Y, Ravindran S, Cooper LF (March 2021). "The importance of cellular and exosomal miRNAs in mesenchymal stem cell osteoblastic differentiation". Scientific Reports. 11 (1): 5953. Bibcode:2021NatSR..11.5953S. doi:10.1038/s41598-021-85306-2. PMC   7960990 . PMID   33723364.
  63. ↑ Villarroya-Beltri C, Gutiérrez-Vázquez C, Sánchez-Cabo F, Pérez-Hernández D, Vázquez J, Martin-Cofreces N, et al. (December 2013). "Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs". Nature Communications. 4 (1): 2980. Bibcode:2013NatCo...4.2980V. doi:10.1038/ncomms3980. PMC   3905700 . PMID   24356509.
  64. 1 2 Villarroya-Beltri C, Baixauli F, Gutiérrez-Vázquez C, Sánchez-Madrid F, Mittelbrunn M (October 2014). "Sorting it out: regulation of exosome loading". Seminars in Cancer Biology. 28: 3–13. doi:10.1016/j.semcancer.2014.04.009. PMC   4640178 . PMID   24769058.
  65. ↑ Thind A, Wilson C (2016). "Exosomal miRNAs as cancer biomarkers and therapeutic targets". Journal of Extracellular Vesicles. 5: 31292. doi:10.3402/jev.v5.31292. PMC   4954869 . PMID   27440105.
  66. 1 2 Liangsupree T, Multia E, Riekkola ML (January 2021). "Modern isolation and separation techniques for extracellular vesicles". Journal of Chromatography A. 1636: 461773. doi: 10.1016/j.chroma.2020.461773 . PMID   33316564.
  67. ↑ Tauro BJ, Greening DW, Mathias RA, Ji H, Mathivanan S, Scott AM, Simpson RJ (February 2012). "Comparison of ultracentrifugation, density gradient separation, and immunoaffinity capture methods for isolating human colon cancer cell line LIM1863-derived exosomes". Methods. 56 (2): 293–304. doi:10.1016/j.ymeth.2012.01.002. PMID   22285593.
  68. ↑ Van Deun J, Mestdagh P, Sormunen R, Cocquyt V, Vermaelen K, Vandesompele J, et al. (2014). "The impact of disparate isolation methods for extracellular vesicles on downstream RNA profiling". Journal of Extracellular Vesicles. 3: 24858. doi:10.3402/jev.v3.24858. PMC   4169610 . PMID   25317274.
  69. ↑ Böing AN, van der Pol E, Grootemaat AE, Coumans FA, Sturk A, Nieuwland R (2014). "Single-step isolation of extracellular vesicles by size-exclusion chromatography". Journal of Extracellular Vesicles. 3: 23430. doi:10.3402/jev.v3.23430. PMC   4159761 . PMID   25279113.
  70. ↑ Li X, Corbett A, Taatizadeh E, et al. (2019). "Challenges and opportunities in exosome research—Perspectives from biology, engineering, and cancer therapy". APL Bioengineering. 3 (1). 011503. doi:10.1063/1.5087122. PMC   6481742 . PMID   31069333.
  71. ↑ Dhondt B, Lumen N, De Wever O, Hendrix A (September 2020). "Preparation of Multi-omics Grade Extracellular Vesicles by Density-Based Fractionation of Urine". STAR Protocols. 1 (2): 100073. doi: 10.1016/j.xpro.2020.100073 . PMC   7580105 . PMID   33111109.
  72. ↑ Dhondt B, Geeurickx E, Tulkens J, Van Deun J, Vergauwen G, Lippens L, et al. (11 March 2020). "Unravelling the proteomic landscape of extracellular vesicles in prostate cancer by density-based fractionation of urine". Journal of Extracellular Vesicles. 9 (1): 1736935. doi: 10.1080/20013078.2020.1736935 . PMC   7144211 . PMID   32284825.
  73. ↑ Geeurickx E, Tulkens J, Dhondt B, Van Deun J, Lippens L, Vergauwen G, et al. (July 2019). "The generation and use of recombinant extracellular vesicles as biological reference material". Nature Communications. 10 (1): 3288. Bibcode:2019NatCo..10.3288G. doi: 10.1038/s41467-019-11182-0 . PMC   6650486 . PMID   31337761.
  74. ↑ Multia E, Tear CJ, Palviainen M, Siljander P, Riekkola ML (December 2019). "Fast isolation of highly specific population of platelet-derived extracellular vesicles from blood plasma by affinity monolithic column, immobilized with anti-human CD61 antibody". Analytica Chimica Acta. 1091: 160–168. Bibcode:2019AcAC.1091..160M. doi:10.1016/j.aca.2019.09.022. hdl: 10138/321264 . PMID   31679569. S2CID   203147714.
  75. ↑ Multia E, Liangsupree T, Jussila M, Ruiz-Jimenez J, Kemell M, Riekkola ML (October 2020). "Automated On-Line Isolation and Fractionation System for Nanosized Biomacromolecules from Human Plasma". Analytical Chemistry. 92 (19): 13058–13065. doi: 10.1021/acs.analchem.0c01986 . PMC   7586295 . PMID   32893620.
  76. ↑ van der Pol E, Hoekstra AG, Sturk A, Otto C, van Leeuwen TG, Nieuwland R (December 2010). "Optical and non-optical methods for detection and characterization of microparticles and exosomes". Journal of Thrombosis and Haemostasis. 8 (12): 2596–607. doi: 10.1111/j.1538-7836.2010.04074.x . PMID   20880256. S2CID   37878753.
  77. ↑ Shao H, Chung J, Balaj L, Charest A, Bigner DD, Carter BS, et al. (December 2012). "Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy". Nature Medicine. 18 (12): 1835–40. doi:10.1038/nm.2994. PMC   3518564 . PMID   23142818.
  78. ↑ Im H, Shao H, Park YI, Peterson VM, Castro CM, Weissleder R, Lee H (May 2014). "Label-free detection and molecular profiling of exosomes with a nano-plasmonic sensor". Nature Biotechnology. 32 (5): 490–5. doi:10.1038/nbt.2886. PMC   4356947 . PMID   24752081.
  79. ↑ Jeong S, Park J, Pathania D, Castro CM, Weissleder R, Lee H (February 2016). "Integrated Magneto-Electrochemical Sensor for Exosome Analysis". ACS Nano. 10 (2): 1802–9. doi:10.1021/acsnano.5b07584. PMC   4802494 . PMID   26808216.
  80. ↑ Shao H, Chung J, Lee K, Balaj L, Min C, Carter BS, et al. (May 2015). "Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma". Nature Communications. 6: 6999. Bibcode:2015NatCo...6.6999S. doi:10.1038/ncomms7999. PMC   4430127 . PMID   25959588.
  81. 1 2 van der Pol E, van Gemert MJ, Sturk A, Nieuwland R, van Leeuwen TG (May 2012). "Single vs. swarm detection of microparticles and exosomes by flow cytometry". Journal of Thrombosis and Haemostasis. 10 (5): 919–30. doi: 10.1111/j.1538-7836.2012.04683.x . PMID   22394434. S2CID   13818611.
  82. ↑ Yuana Y, Oosterkamp TH, Bahatyrova S, Ashcroft B, Garcia Rodriguez P, Bertina RM, Osanto S (February 2010). "Atomic force microscopy: a novel approach to the detection of nanosized blood microparticles". Journal of Thrombosis and Haemostasis. 8 (2): 315–23. doi: 10.1111/j.1538-7836.2009.03654.x . PMID   19840362. S2CID   5963526.
  83. ↑ Dragovic RA, Gardiner C, Brooks AS, Tannetta DS, Ferguson DJ, Hole P, et al. (December 2011). "Sizing and phenotyping of cellular vesicles using Nanoparticle Tracking Analysis". Nanomedicine. 7 (6): 780–8. doi:10.1016/j.nano.2011.04.003. PMC   3280380 . PMID   21601655.
  84. ↑ Tatischeff I, Larquet E, Falcón-Pérez JM, Turpin PY, Kruglik SG (2012). "Fast characterisation of cell-derived extracellular vesicles by nanoparticles tracking analysis, cryo-electron microscopy, and Raman tweezers microspectroscopy". Journal of Extracellular Vesicles. 1: 19179. doi:10.3402/jev.v1i0.19179. PMC   3760651 . PMID   24009887.
  85. ↑ Pathan M, Keerthikumar S, Ang CS, Gangoda L, Quek CY, Williamson NA, et al. (August 2015). "FunRich: An open access standalone functional enrichment and interaction network analysis tool". Proteomics. 15 (15): 2597–601. doi:10.1002/pmic.201400515. PMID   25921073. S2CID   28583044.
  86. ↑ Gaur P, Chaturvedi A (2016). "Mining SNPs in extracellular vesicular transcriptome of Trypanosoma cruzi: a step closer to early diagnosis of neglected Chagas disease". PeerJ. 4: e2693. doi: 10.7717/peerj.2693 . PMC   5126619 . PMID   27904804.
  87. ↑ Han C, Sun X, Liu L, Jiang H, Shen Y, Xu X, et al. (2016). "Exosomes and Their Therapeutic Potentials of Stem Cells". Stem Cells International. 2016: 7653489. doi: 10.1155/2016/7653489 . PMC   4684885 . PMID   26770213.
  88. ↑ Yeo RW, Lim SK (2016). "Exosomes and their Therapeutic Applications.". In Huss R, Guenther C, Hauser JA (eds.). Advances In Pharmaceutical Cell Therapy: Principles Of Cell-based Biopharmaceuticals. Singapore: World Scientific. pp. 477–501. ISBN   978-981-4616-80-5.
  89. ↑ Di Rocco G, Baldari S, Toietta G (2016). "Towards Therapeutic Delivery of Extracellular Vesicles: Strategies for In Vivo Tracking and Biodistribution Analysis". Stem Cells International. 2016: 5029619. doi: 10.1155/2016/5029619 . PMC   5141304 . PMID   27994623.
  90. ↑ Elahi FM, Farwell DG, Nolta JA, Anderson JD (January 2020). "Preclinical translation of exosomes derived from mesenchymal stem/stromal cells". Stem Cells. 38 (1): 15–21. doi: 10.1002/stem.3061 . PMC   7004029 . PMID   31381842.
  91. ↑ Basu J, Ludlow JW (2016). "Exosomes for repair, regeneration and rejuvenation". Expert Opinion on Biological Therapy. 16 (4): 489–506. doi:10.1517/14712598.2016.1131976. PMID   26817494. S2CID   10370397.
  92. ↑ "MSC-derived Exosomes Promote Bone Fracture Repair". Stem Cells Portal. 2 January 2017.
  93. ↑ Silva AM, Teixeira JH, Almeida MI, Gonçalves RM, Barbosa MA, Santos SG (February 2017). "Extracellular Vesicles: Immunomodulatory messengers in the context of tissue repair/regeneration". European Journal of Pharmaceutical Sciences. 98: 86–95. doi:10.1016/j.ejps.2016.09.017. PMID   27644894. S2CID   207686963.
  94. ↑ Blazquez R, Sanchez-Margallo FM, de la Rosa O, Dalemans W, Alvarez V, Tarazona R, Casado JG (2014). "Immunomodulatory Potential of Human Adipose Mesenchymal Stem Cells Derived Exosomes on in vitro Stimulated T Cells". Frontiers in Immunology. 5: 556. doi: 10.3389/fimmu.2014.00556 . PMC   4220146 . PMID   25414703.
  95. ↑ Álvarez V, Sánchez-Margallo FM, Macías-García B, Gómez-Serrano M, Jorge I, Vázquez J, et al. (October 2018). "The immunomodulatory activity of extracellular vesicles derived from endometrial mesenchymal stem cells on CD4+ T cells is partially mediated by TGFbeta". Journal of Tissue Engineering and Regenerative Medicine. 12 (10): 2088–2098. doi: 10.1002/term.2743 . hdl: 20.500.12105/9957 . PMID   30058282. S2CID   51864647.
  96. ↑ Blázquez R, Sánchez-Margallo FM, Álvarez V, Usón A, Marinaro F, Casado JG (April 2018). "Fibrin glue mesh fixation combined with mesenchymal stem cells or exosomes modulates the inflammatory reaction in a murine model of incisional hernia". Acta Biomaterialia. 71: 318–329. doi:10.1016/j.actbio.2018.02.014. PMID   29462710.
  97. ↑ Casado JG, Blázquez R, Vela FJ, Álvarez V, Tarazona R, Sánchez-Margallo FM (2017). "Mesenchymal Stem Cell-Derived Exosomes: Immunomodulatory Evaluation in an Antigen-Induced Synovitis Porcine Model". Frontiers in Veterinary Science. 4: 39. doi: 10.3389/fvets.2017.00039 . PMC   5359696 . PMID   28377922.
  98. ↑ Shabbir A, Cox A, Rodriguez-Menocal L, Salgado M, Van Badiavas E (July 2015). "Mesenchymal Stem Cell Exosomes Induce Proliferation and Migration of Normal and Chronic Wound Fibroblasts, and Enhance Angiogenesis In Vitro". Stem Cells and Development. 24 (14): 1635–47. doi:10.1089/scd.2014.0316. PMC   4499790 . PMID   25867197.
  99. ↑ Geiger A, Walker A, Nissen E (November 2015). "Human fibrocyte-derived exosomes accelerate wound healing in genetically diabetic mice". Biochemical and Biophysical Research Communications. 467 (2): 303–9. doi:10.1016/j.bbrc.2015.09.166. PMID   26454169.
  100. ↑ Sjöqvist S, Ishikawa T, Shimura D, Kasai Y, Imafuku A, Bou-Ghannam S, et al. (20 January 2019). "Exosomes derived from clinical-grade oral mucosal epithelial cell sheets promote wound healing". Journal of Extracellular Vesicles. 8 (1): 1565264. doi:10.1080/20013078.2019.1565264. PMC   6346716 . PMID   30719240.
  101. ↑ Wahlgren J, Statello L, Skogberg G, Telemo E, Valadi H (2016). "Delivery of Small Interfering RNAs to Cells via Exosomes". SiRNA Delivery Methods. Methods in Molecular Biology. Vol. 1364. pp. 105–25. doi:10.1007/978-1-4939-3112-5_10. ISBN   978-1-4939-3111-8. PMID   26472446.
  102. ↑ Kumar L, Verma S, Vaidya B, Gupta V (2015). "Exosomes: Natural Carriers for siRNA Delivery". Current Pharmaceutical Design. 21 (31): 4556–65. doi:10.2174/138161282131151013190112. PMID   26486142.
  103. ↑ Bell BM, Kirk ID, Hiltbrunner S, Gabrielsson S, Bultema JJ (January 2016). "Designer exosomes as next-generation cancer immunotherapy". Nanomedicine. 12 (1): 163–9. doi:10.1016/j.nano.2015.09.011. PMID   26500074.
  104. 1 2 3 Shao X, Zhang M, Chen Y, Sun S, Yang S, Li Q (2023). "Exosome-mediated delivery of superoxide dismutase for anti-aging studies in Caenorhabditis elegans". International Journal of Pharmaceutics. 641: 123090. doi:10.1016/j.ijpharm.2023.123090. PMID   37268030. S2CID   259039593.
  105. ↑ Askenase, Philip W., Artificial nanoparticles are not as good as the real thing , Outlook, Nature, June 17, 2020
  106. ↑ Batrakova EV, Kim MS (December 2015). "Using exosomes, naturally-equipped nanocarriers, for drug delivery". Journal of Controlled Release. 219: 396–405. doi:10.1016/j.jconrel.2015.07.030. PMC   4656109 . PMID   26241750.
  107. ↑ Kim MS, Haney MJ, Zhao Y, Mahajan V, Deygen I, Klyachko NL, et al. (April 2016). "Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells". Nanomedicine. 12 (3): 655–664. doi:10.1016/j.nano.2015.10.012. PMC   4809755 . PMID   26586551.
  108. ↑ Center for Biologics Evaluation and Research (2019-12-20). "Public Safety Notification on Exosome Products". FDA.
  109. ↑ Knoepfler P (2020-04-23). "Kimera Labs FDA letter cites exosomes for COVID-19, more issues". The Niche. Retrieved 2021-03-02.
  110. ↑ "Limited Reporting of Adverse Events Tied to Regenerative Treatments Leaves Consumers Vulnerable". pew.org. 31 July 2020. Retrieved 2021-03-02.
  111. ↑ "FDA Warning Letters Week of 4/20/2020: PMA, IDE, & Untitled Letter to Stem Cell Firm". Redica. 2020-04-27. Retrieved 2021-03-02.
  112. ↑ Mathivanan S, Simpson RJ (November 2009). "ExoCarta: A compendium of exosomal proteins and RNA". Proteomics. 9 (21): 4997–5000. doi:10.1002/pmic.200900351. PMID   19810033. S2CID   22275212.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.